One of the first companies to move into the BioEscalator when it opened its doors, PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, has relocated to Boston, USA.
PepGen raised $112.5M in August of 2021, and the funding allowed the expansion of PepGen's team in its headquarters in Boston. The new PepGen headquarters will manage late-stage pre-clinical testing and clinical and regulatory functions.
Caroline Godfrey, co-founder and previous CEO of PepGen, has recently been appointed to the company's scientific advisory board. She will continue contributing to PepGen's science as the company continues to expand in its new location.